Patients' perspectives towards biologic dose reduction in psoriasis: a qualitative study.

"Declarations Conflict of interestLS van der Schoot carries out clinical trials for Janssen and Novartis and received speaking fees from Janssen and Eli Lilly. All funding is not personal but goes to the independent Research Fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, The Netherlands. MMB Seyger received grants from/was involved in clinical trials from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma and Pfizer. She served as a consultant for Abbvie, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer an UCB; fees were paid directly to the institution. EMGJ de Jong has received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands from AbbVie, Pfizer, Novartis, Janssen Pharmaceuticals and Leo Pharma and has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including AbbVie, Janssen Pharmaceutica, Novartis, Lily, Celgene, Leo Pharma, UCB and Almirall. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands. JMPA van den Reek carries out clinical trials for AbbVie, Celgene and Janssen; has received speaking fees/attended advisory boards from AbbVie, BMS, Almirall and Janssen and has received reimbursement for attending a symposium from Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands. The other authors declare no conflict of interests. Ethical approvalProcedures performed in studies involving human participants were in accordance with the ethical standards and applicable laws and regulations including the Declaration of Helsinki. IRB approval statusThe need for ethical approval for the current study was waived by the medical ethical committee Arnhem-Nijmegen (2021-12967). Written informed consent was obtained from all participants. Conflict of interest LS van der Schoot carries out clinical trials for Janssen and Novartis and received speaking fees from Janssen and Eli Lilly. All funding is not personal but goes to the independent Research Fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, The Netherlands. MMB Seyger received grants from/was involved in clinical trials from Abbvie, Amgen, Celgene, Eli Lilly, Janssen, Leo Pharma and Pfizer. She served as a consultant for Abbvie, Eli Lilly, Janssen, Leo Pharma, Novartis, Pfizer an UCB; fees were paid directly to the institution. EMGJ de Jong has received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands from AbbVie, Pfizer, Novartis, Janssen Pharmaceuticals and Leo Pharma and has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including AbbVie, Janssen Pharmaceutica, Novartis, Lily, Celgene, Leo Pharma, UCB and Almirall. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands. JMPA van den Reek carries out clinical trials for AbbVie, Celgene and Janssen; has received speaking fees/attended advisory boards from AbbVie, BMS, Almirall and Janssen and has received reimbursement for attending a symposium from Celgene and AbbVie. All funding is not personal but goes to the independent research fund of the Department of Dermatology of the Radboud University Medical Center Nijmegen, the Netherlands. The other authors declare no conflict of interests."

"Funding This study was partly funded by ZonMw, the Hague, the Netherlands."